The company has 18.44
B in debt with debt to equity (D/E) ratio of 0.55, which is OK given its current industry classification.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Abbott Laboratories has an asset utilization ratio of 90.53 percent. This implies that the company is making $0.91 for each dollar of assets. An increasing asset utilization means that Abbott Laboratories is more efficient with each dollar of assets it utilizes for everyday operations.
We determine the current worth of Highland Longshort Healthcare using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this mutual fund, attempts to find the value of Highland Long/short based exclusively on its
fundamental and basic
technical indicators. By analyzing Highland Long/short's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Highland Long/short's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Highland Long/short. We calculate exposure to Highland Long/short's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Highland Long/short's related companies.
Highland Long/short Investment Alerts
Highland investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Highland Longshort Healthcare performance across your portfolios.Please check all
investment alerts for Highland
Highland Long/short Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Highland value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Highland Long/short competition to find
correlations between indicators driving the intrinsic value of Highland.
Instrument Allocation
The asset allocation of funds such as Highland Long/short usually varies among a different mix of asset classes. Balanced mutual funds invest not only in bonds, which focus primarily on income, and stocks, which aim for investment growth, but also keep some reserve in cash or even exotic instruments. Below we show the current asset allocation of Highland Longshort Healthcare
DetailsBreaking down Highland Long/short Indicators
Abbott Laboratories reported the last year's revenue of 37.34
B. Total Income to common stockholders was 5.69
B with profit before taxes, overhead, and interest of 19.61
B.
Margins Breakdown
Abbott profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Abbott Laboratories itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Abbott Laboratories profit margins.
| Operating Margin | 16.28 |
| EBITDA Margin | 0.25 |
| Gross Margin | 0.62 |
| Profit Margin | 0.13 |
Abbott Laboratories Average Assets is increasing over the last 8 years. The newest value of Abbott Laboratories Average Assets is 69,659,064,921. Abbott Laboratories Average Assets is increasing over the last 8 years. The previous year's value of Abbott Laboratories Average Assets was 69,659,064,921.
Abbott technical analysis implies possible bounce-back
Newest Treynor Ratio is up to -0.06. Price may drop again. Abbott Laboratories exhibits very low volatility with skewness of -0.61 and kurtosis of 1.03. However, we advise investors to further study Abbott Laboratories technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Abbott Laboratories' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Abbott Laboratories' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
The Current Takeaway on Abbott Laboratories Investment
Whereas other companies under the medical devices industry are still a bit expensive, Abbott Laboratories may offer a potential longer-term growth to private investors. The inconsistency in the assessment between current Abbott valuation and our trade advice on Abbott Laboratories is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Abbott Laboratories.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Highland Longshort Healthcare. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
